List of Excipients in API darifenacin hydrobromide
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing darifenacin hydrobromide
Detailed excipient profiles for darifenacin hydrobromide
Excipient focus: ANHYDROUS DIBASIC CALCIUM PHOSPHATE
darifenacin hydrobromide drug variants containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
| Company | Ingredient | NDC |
|---|---|---|
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| Xiromed LLC | darifenacin hydrobromide | 70700-182 |
| Alan Laboratories Inc | darifenacin hydrobromide | 70754-161 |
| Proficient Rx LP | darifenacin hydrobromide | 71205-900 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| >Company | >Ingredient | >NDC |
Excipient focus: CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
darifenacin hydrobromide drug variants containing CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
| Company | Ingredient | NDC |
|---|---|---|
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| Xiromed LLC | darifenacin hydrobromide | 70700-182 |
| Alan Laboratories Inc | darifenacin hydrobromide | 70754-161 |
| Proficient Rx LP | darifenacin hydrobromide | 71205-900 |
| >Company | >Ingredient | >NDC |
Excipient focus: D&C YELLOW NO. 10
darifenacin hydrobromide drug variants containing D&C YELLOW NO. 10
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing D&C YELLOW NO. 10
Excipient focus: FD&C YELLOW NO. 6
darifenacin hydrobromide drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing FD&C YELLOW NO. 6
Excipient focus: HYPROMELLOSE 2208
darifenacin hydrobromide drug variants containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| Xiromed LLC | darifenacin hydrobromide | 70700-182 |
| Alan Laboratories Inc | darifenacin hydrobromide | 70754-161 |
| Proficient Rx LP | darifenacin hydrobromide | 71205-900 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
darifenacin hydrobromide drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| Alan Laboratories Inc | darifenacin hydrobromide | 70754-161 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| Xiromed LLC | darifenacin hydrobromide | 70700-182 |
| Proficient Rx LP | darifenacin hydrobromide | 71205-900 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
darifenacin hydrobromide drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing HYPROMELLOSES
Excipient focus: LACTOSE MONOHYDRATE
darifenacin hydrobromide drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| Xiromed LLC | darifenacin hydrobromide | 70700-182 |
| Alan Laboratories Inc | darifenacin hydrobromide | 70754-161 |
| Proficient Rx LP | darifenacin hydrobromide | 71205-900 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
darifenacin hydrobromide drug variants containing MAGNESIUM STEARATE
darifenacin hydrobromide drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MALTODEXTRIN
darifenacin hydrobromide drug variants containing MALTODEXTRIN
| Company | Ingredient | NDC |
|---|---|---|
| Xiromed LLC | darifenacin hydrobromide | 70700-182 |
| Alan Laboratories Inc | darifenacin hydrobromide | 70754-161 |
| Proficient Rx LP | darifenacin hydrobromide | 71205-900 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing MALTODEXTRIN
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| >Company | >Ingredient | >NDC |
Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES
darifenacin hydrobromide drug variants containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Xiromed LLC | darifenacin hydrobromide | 70700-182 |
| Alan Laboratories Inc | darifenacin hydrobromide | 70754-161 |
| Proficient Rx LP | darifenacin hydrobromide | 71205-900 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYDEXTROSE
darifenacin hydrobromide drug variants containing POLYDEXTROSE
| Company | Ingredient | NDC |
|---|---|---|
| Xiromed LLC | darifenacin hydrobromide | 70700-182 |
| Alan Laboratories Inc | darifenacin hydrobromide | 70754-161 |
| Proficient Rx LP | darifenacin hydrobromide | 71205-900 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing POLYDEXTROSE
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
darifenacin hydrobromide drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing POLYETHYLENE GLYCOL
Excipient focus: POLYETHYLENE GLYCOL 400
darifenacin hydrobromide drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| POLYGEN PHARMACEUTICALS INC | darifenacin hydrobromide | 52605-067 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing POLYETHYLENE GLYCOL 400
Excipient focus: POLYETHYLENE GLYCOL 4000
darifenacin hydrobromide drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Cipla USA Inc | darifenacin hydrobromide | 69097-431 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing POLYETHYLENE GLYCOL 4000
Excipient focus: POLYETHYLENE GLYCOL 8000
darifenacin hydrobromide drug variants containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| Jubilant Cadista Pharmaceuticals Inc | darifenacin hydrobromide | 59746-516 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing POLYETHYLENE GLYCOL 8000
Excipient focus: POLYVINYL ALCOHOL
darifenacin hydrobromide drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | darifenacin hydrobromide | 10370-170 |
| >Company | >Ingredient | >NDC |
darifenacin hydrobromide drug variants not containing POLYVINYL ALCOHOL
Excipient focus: TALC
darifenacin hydrobromide drug variants containing TALC
darifenacin hydrobromide drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
darifenacin hydrobromide drug variants containing TITANIUM DIOXIDE
darifenacin hydrobromide drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
